At least ten different oncolytic viruses have entered clinical testing. A study published in the January 2004 issue of the journal *Nature Biotechnology,* now reports that native Sindbis virus exhibits oncolytic characteristics. The virus was effective at killing tumors in mice, while leaving normal tissues unaffected.

Sindbis is transmitted exclusively by mosquitoes, which bite and infect humans and other animals. In humans, the virus causes cold-like symptoms. Unlike most of the other cancer-killing viruses, which have to undergo some kind of genetic manipulation to target cancer cells, unmodified Sindbis was effective at killing a variety of tumors. Moreover, the virus was able to home to the tumor cells even after injection distally into the bloodsteam. The authors demonstrated systemic vector targeting of tumors growing subcutaneously, intrapancreatically, intraperitoneally and in the lungs. The vectors could also target syngeneic and spontaneous tumors in immune-competent mice.

The amount of time and the number of injections needed to cause tumor remission varied for different types of cancer, but in general mice were given injections of the virus daily. Within one to two months, many tumors had disappeared.

"Nature gave us a gift in Sindbis," says principal investigator of the study, Dr. Daniel Meruelo. "It has a natural ability to infect tumor cells almost exclusively, and naturally induces cell death in these tumor cells."

Computer-generated image of the outer structure of the Sindbis virus. Courtesy of Angel Paredes, University of Texas Medical Branch and Dennis Brown, North Carolina State University.

Sindbis enters cells through a receptor for laminin, which is often overexpressed in cancer cells. Dr. Meruelo theorizes that since tumor cells are far more likely than healthy cells to have free laminin receptors on their surfaces, they are more likely to take up the virus.

Tumors imaged within the body cavities of mice. While all tumors were originally of a similar size, those tumors injected with Sindbis virus (middle row), or Sindbis virus expressing recombinant IL- 12 (bottom row), four days prior to imaging showed significant reduction of tumor size relative to untreated mice (top row).

The workers also engineered the virus to express IL-12. The combination was even more effective than Sindbis alone at killing tumors, and it did not poison surrounding areas.

The study involved tumors in mice, and the virus has yet to be tested in humans. Meruelo hopes to begin clinical trials of the virus within about two years, but he stresses that there is still far more work to be done before the virus can be shown to be safe for human application, let alone an effective treatment for human tumors.

*Nature Biotechnology,* online edition, doi: 10.1038/nbt917

Fatty Acid Imbalance Found in CF Patients {#cesec10}
=========================================

Cystic fibrosis (CF) patients have an imbalance of fatty acids in their tissues, according to a study appearing in the 5 February 2004 issue of the *New England Journal of Medicine.* The findings extend previous observations from mouse studies and show that the same fatty acid abnormality occurs in humans with CF, is related to the degree of abnormality in the gene, and is not a consequence of inflammation.

Characterized by chronic inflammation of the lungs, CF results in the production of an abnormally thick, sticky mucus, which leads to the development of life-threatening lung infections. Although it was initially thought that infection itself led to eventual lung failure in CF patients, it is now recognized that an excessive host inflammatory response plays a major role in the process.

Certain fatty acids, such as arachidonic acid (AA) and docosahexaenoic (DHA) acid, are important in controlling the inflammatory responses. Earlier animal studies gave the first indications of the fatty acid imbalances in CF. In the new study, the researchers examined tissue samples of 38 CF patients. As predicted, the results showed that there were abnormally high levels of arachidonic acid and abnormally low levels of docosahexaenoic acid.

"It is known that high amounts of AA and low amounts of DHA would predispose to inflammation," explains study senior author, Steven Freedman. "This discovery may help explain why there is an excessive inflammatory response among CF patients. This is the basis for why Omega-3 fish oils, found in cold-water fish as well assupplements, reduce inflammation since they increase levels of DHA and suppress AA."

The parents of CF parents had fatty acid levels half-way between those of the patients and the unaffected control subjects. The fact that individuals who carry the CF gene--- but are otherwise healthy---have levels of AA and DHA midway between normal controls and CF patients is consistent with our hypothesis that a fatty acid defect is a basic problem in CF, and not just a reflection of a disease state," explains co-author Brian O\'Sullivan. Freedman cautions that exceptionally high doses of DHA were required to treat the CF mice in the animal study, and that over-the- counter supplements would not be beneficial and could be harmful at the high doses required to achieve clinical effectiveness.

*The New England Journal of Medicine,* (2004), **350:** 560-9, doi not provided by publisher.

Making New Skin Gets a Little Easier {#cesec20}
====================================

The ability to regenerate epidermal tissue has been thought to depend upon epidermal stem cells, due to their ability to self-renew and generate differentiated progeny. However, new research in the 2 February 2004 issue of the *Journal of Clinical Investigation* has demonstrated that both epidermal stems cells and their early, differentiated progeny can contribute to rapid epidermal regeneration.

The epidermis is the outermost layer of the skin and is made up primarily of keratinocytes. Skin grafts using cultured human epidermal cells have successfully treated patients with severe skin wounds. The majority of proliferating epidermal cells---also known as transit-amplifying cells---at the innermost layer of the skin have a finite life span, and undergo rapid terminal differentiation. Therefore, it had been thought that the extensive regenerative capacity of the skin is most likely attributed to the activity of epidermal stem cells.

Pritinder Kaur and colleagues separated epidermal stem cells from their progeny and assayed the ability of both cell types to regenerate epidermal tissue both *in vitro* and *in vivo.* As expected, keratinocyte stem cells displayed robust regenerative capacity. Unexpectedly, transit-amplifying cells and early differentiating cells, which are more committed progenitor cells, also formed a fully stratified epidermis under appropriate conditions. The authors also demonstrated that the regenerative capacity of these cell types could be enhanced by exposure to the protein, laminin-10/11.

This work presents new considerations for the expansion of keratinocyte progenitor cell populations for therapies that require large numbers of epidermal cells, such as for the treatment of severe wounds such as extensive burns. It may be possible to harness the vast proliferative potential of readily available and accessible keratinocyte progenitors of the skin for cellular therapies, thereby removing the need for difficult and limited stem cell selection.

*The Journal of Clinical Investigation,* online edition, doi: 10.1072/JCI200419140

Antibody Neutralizes SARS Virus {#cesec30}
===============================

Researchers have isolated an antibody from a library of human monoclonal antibodies that can block infection by the SARS virus in laboratory tests. The antibody neutralized SARS infection by blocking the virus from entering cultured cells. The findings will be posted the week of 2 February 2004 in the early online edition of the *Proceedings of the National Academy of Sciences.*

SARS (severe acute respiratory syndrome) is a highly contagious illness that often progresses to pneumonia and is sometimes fatal. First reported in Asia in February 2003, in the next few months it spread worldwide--- infecting nearly 8,100 people before it was contained.

The SARS virus-specific human monoclonal antibody was isolated from a human antibody phage display library containing nearly 27 billion monoclonal antibodies generated from a mixture of blood cells from 57 human donors. From this large collection, the workers isolated eight antibodies that recognized and bound to the S1 protein, a building block of the virus' "spike" structure that enables it to infect host cells. One of the antibodies (labeled the 80R antibody) potently blocked live SARS viruses from entering cultured human cells. Further studies revealed that the antibody prevented infection through high-affinity binding to the S1 protein\'s receptor binding domain.

Experiments are continuing in animal models of SARS. The paper\'s senior author, Wayne Marasco, says the 80R antibody looks promising in these tests and could be commercially developed for testing in clinical trials. The discovery may expedite the development of an antibody drug for the prevention or early treatment of SARS. Human monoclonal antibodies are an important tool for passive immunization or early treatment of a viral infection.

"This is really a proof of principle for responding to emerging infectious diseases," says Marasco. "If the international community works together, it can make a serious dent in the time it takes to develop protective treatments against these threats."

*The Proceedings of the National Academy of Sciences,* online edition, doi: 10.1073/pnas.0307140101
